详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Dong, Xiaorong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Chen, Jianhua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Yu, Yan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Hu, Jie[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Li, Xingya[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Cheng, Ying[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Yao, Wenxiu[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]

; Hu, Yanping[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wang, Qiming[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Lu, Junguo[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Zheng, Wei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]

; Yu, Xinmin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Zhang, Peng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]

; Yu, Zhuang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wei, Hongying[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Li, Chuan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Huang, Qiqi[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Tao, Mengyuan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wu, Qiong[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Lu, Shun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ;

机构： [1]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China [2]Hunan Canc Hosp, Changsha, Peoples R China [3]Harbin Med Univ Canc Hosp, Harbin, Peoples R China [4]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China [5]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China [6]Jilin Canc Hosp, Changchun, Jilin, Peoples R China [7]Sichuan Canc Hosp, Chengdu, Peoples R China [8]Hubei Canc Hosp, Wuhan, Peoples R China [9]Henan Canc Hosptal, Zhengzhou, Peoples R China [10]Nantong Tumor Hosp, Nantong, Peoples R China [11]China Med Univ, ShengJing Hosp, Shenyang, Peoples R China [12]Zhejiang Canc Hosp, Hangzhou, Peoples R China [13]Shanghai Pulm Hosp, Shanghai, Peoples R China [14]Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China [15]Hansoh Pharmaceut Grp Co Ltd, Shanghai, Peoples R China [16]Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

出处：

ISSN：

基金：

语种：

WOS：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2023]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China [2]Hunan Canc Hosp, Changsha, Peoples R China [3]Harbin Med Univ Canc Hosp, Harbin, Peoples R China [4]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China [5]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China [6]Jilin Canc Hosp, Changchun, Jilin, Peoples R China [7]Sichuan Canc Hosp, Chengdu, Peoples R China [8]Hubei Canc Hosp, Wuhan, Peoples R China [9]Henan Canc Hosptal, Zhengzhou, Peoples R China [10]Nantong Tumor Hosp, Nantong, Peoples R China [11]China Med Univ, ShengJing Hosp, Shenyang, Peoples R China [12]Zhejiang Canc Hosp, Hangzhou, Peoples R China [13]Shanghai Pulm Hosp, Shanghai, Peoples R China [14]Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China [15]Hansoh Pharmaceut Grp Co Ltd, Shanghai, Peoples R China [16]Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Phase 1b study of HS-10241 combined with almonertinib in pre-treated advanced nonsmall cell lung cancer (NSCLC) harboring EGFR mutation

文献详情